Antifungals Market Report 2026

Antifungals Market Overview

• Antifungals market size has reached to $29.6 billion in 2025 • Expected to grow to $44.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Prevalence Of Fungal Infections Driving Market Growth Due To Increased Need For Effective Antifungal Therapies • Market Trend: Formulating Once‑Weekly Echinocandins For Treatment Of Serious Fungal Infections • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Antifungals Market?

The antifungal drugs refer to drugs that are used to detect and eliminate fungal pathogens. The fungal pathogens thrive in the body in unhygienic and unclean environments. These drugs are also known as antimycotic medications, used to treat and prevent mycoses such as athlete's foot, ringworm, candidiasis (thrush), and serious systemic infections such as cryptococcal meningitis, and others. The main types of drugs in antifungals are echinocandins, azoles, polyenes, and allylamines. Echinocandins are a new type of antifungal medication that works by inhibiting the formation of 1,3-D-glucan, a key component of the fungal cell wall, in an entirely fungal-specific manner. The different routes of administration include oral, parenteral, and topical and involve various therapeutic indications such as aspergillosis, dermatophytosis, candidiasis, and others. The several sectors include hospitals and clinics, dermatology clinics, and other users.

What Is The Antifungals Market Growth Forecast?

The antifungals market size is expected to see strong growth in the next few years. It will grow to $44.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growth in systemic fungal infections, antifungal resistance concerns, demand for safer therapies, expansion of hospital care, increased diagnosis rates. Major trends in the forecast period include rising prevalence of fungal infections, growing demand for broad-spectrum antifungals, expansion of topical antifungal treatments, increased use in immunocompromised patients, development of novel antifungal drug classes.

What Are The Drivers Of The Antifungals Market?

The increasing prevalence of fungal infections is expected to propel the growth of the antifungals market going forward. Fungal infections are diseases caused by the invasion and growth of fungi in or on the body which affects various parts of the body, including the skin, nails, lungs, and mucous membranes. The rising prevalence of fungal infections is due to climate change creating favorable conditions for fungi to spread and adapt to higher temperatures, increasing human exposure and infection risks. Antifungals play a crucial role in treating fungal diseases by inhibiting the growth and reproduction of fungi, either by disrupting their cell wall or membrane, blocking essential enzymatic processes, or interfering with their ability to synthesize vital components, thereby reducing fungal load, alleviating symptoms, and preventing the spread of infection within the body. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government department, bloodstream infections caused by yeast increased by 4% in 2024 compared with 2023, rising from 2,170 reported cases to 2,247. Therefore, the increasing incidence of fungal infections is driving the growth of the antifungals industry. The increasing healthcare infrastructure is expected to propel the growth of antifungals market going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, and systems that support the delivery of healthcare services. Rising healthcare infrastructure is primarily due to increased government support and investments through various policies and incentives, which promote development of healthcare facilities. Healthcare infrastructure encompasses the necessary facilities, systems, and resources for delivering healthcare services for the effective management of fungal infections. For instance, in May 2024, according to Baker McKenzie, an Australia based law firm, the Australian government allocated $1.82 billion (AUD 2.8 billion) to strengthen Medicare, building on the $3.95 billion (AUD 6.1 billion) Medicare investment in the 2023-24 Federal Budget, and USD 91.48million (AUD 141.1 million) for medical research and services for people with chronic conditions such as bowel and skin cancer, diabetes, and dementia. Therefore, the increasing healthcare infrastructure is propelling the growth of antifungals industry going forward.

Key Players In The Global Antifungals Market

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

Global Antifungals Market Trends and Insights

Major companies operating in the antifungals market are focusing on product innovation and formulation such as long‑acting echinocandin therapies, to improve patient adherence, reduce dosing frequency, and address unmet clinical needs in invasive fungal infections. By extending the half-life and modifying pharmacokinetics, these next‑generation antifungals offer effective fungal suppression with more convenient administration schedules. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, along with Melinta Therapeutics (U.S.), announced FDA approval for REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis. Rezafungin is a once‑weekly echinocandin, offering non-inferior efficacy compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while maintaining a comparable safety profile. The extended dosing potential of REZZAYO addresses a critical gap in antifungal therapy, improving treatment continuity and reducing hospital burden in acute‑care settings.

What Defines the Antifungals Market?

The antifungal market consists of sales of clotrimazole, miconazole, and ketoconazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antifungals Market Report 2026?

The antifungals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antifungals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.